Oncodesign Société Anonyme, a biopharmaceutical company, conducts research and development work on new therapeutic and diagnostic tools with pharmaceutical firms, biotech companies, public research institutions, and investment groups. It offers integrated drug discovery services; in vitro and in vivo pharmacology services; services for studying the metabolism and pharmacokinetics of drug candidates; and translational biomarkers, biodecontamination/biosafety, and biobanking services. The company also engages in the analysis of new chemical and biological entities, and membrane proteins; and immuno analysis and monitoring, and microbiological monitoring activities. In addition, it engages in the kinase inhibitor development programs, and licensing of Kinase inhibitors in oncology, and CNS and inflammation technologies. Oncodesign Société Anonyme has a strategic partnership with InterSystems for new treatments in the field of oncology; and Covalab. The company also has a collaboration agreement with TiumBio Co., Ltd. for the research and development of fibrosis drug candidates. Oncodesign Société Anonyme was founded in 1995 and is headquartered in Dijon, France.

ALON

EURONEXT:ALONC

Oncodesign Société Anonyme

Last Close

14.42

08/12 16:35

Volume Today

90.13K

Avg: 48.40K

PE Ratio

−448.96

PFCF: -

Filings Not Available